Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
8/9/2017Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test
CINCINNATI, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has initiated clinical trials for a new illumigene CMV molecular amplification test. This assay is designed to specifically detect the congenital Cytomegalovirus (CMV) infection in newborns from saliva. Presently, there is no FDA-cleared test for CMV screening in newborns. Meridian has enrolled an international team of world experts in neonatal CMV infections in order to support the cl... 
 Printer Friendly Version
8/8/2017Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of its ImmunoCard STAT!® product line with the addition of ImmunoCard STAT! FLU A&B. The ImmunoCard STAT! FLU A&B product is CLIA waived and meets the new FDA reclassification requirements. ImmunoCard STAT! FLU A&B detects the presence of influenza A & B in nasal and nasopharyngeal swabs. The product can also be used to test aspirates and nasal washes. The ImmunoC... 
 Printer Friendly Version
8/8/2017Meridian Bioscience Elects John Rice to the Board of Directors
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Board of Directors elected a new independent director, John M. Rice, Ph.D., effective August 8, 2017. Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies. Since 2014, Mr. Rice has served as the Director of Life Sciences at ... 
 Printer Friendly Version
8/2/2017Bioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing
CINCINNATI, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio today for Next-Generation Sequencing (NGS) library preparation. The new JetSeq Clean Kit is a clean-up system based on paramagnetic bead technology, designed for efficient purification of nucleic acid fragments in the next-generation sequencing workflow. JetSeq Clean removes salts, primers,... 
 Printer Friendly Version
7/27/2017Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge
GENERAL HIGHLIGHTS CINCINNATI, July 27, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fiscal 2017 third quarter and first nine months net revenues of $50.1 and $151.1 million, respectively, a decrease of 1% and an increase of 1%, respectively, from the same periods of the prior fiscal year;   reported third quarter operating income of $4.3 million (including a $6.6 million non-cash goodwill impairment charge), a decrease of 69% from the same period ... 
 Printer Friendly Version
7/20/2017Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China
CINCINNATI, July 20, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the opening of Meridian Bioscience Beijing, LLC, its wholly foreign owned enterprise (WFOE) in Beijing, China. Meridian opened a representative office (RO) in Beijing in 2015, and now this office has been transitioned to a WFOE to better serve its Chinese customers. The office is located on Chang-An Avenue (close to Tiananmen Square and government offices) in the New China Life Insurance (NCI)... 
 Printer Friendly Version
7/13/2017Meridian Bioscience Comments on Recent FDA Press Statement
CINCINNATI, July 13, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following comments regarding the FDA press statement and website announcement concerning the posting of the Form FDA-483 issued following the inspection of Magellan Diagnostics, which closed on June 29, 2017.  As FDA noted, this Form represents the investigators’ observations and is not a final Agency determination.  Consistent with FDA policy, Magellan will promptl... 
 Printer Friendly Version
6/30/2017Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics
CINCINNATI, June 30, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. is providing the following clarifying comments regarding a June 29, 2017 letter from a group of U.S. Senators to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).  The letter requested information on an FDA Safety Notification released in May 2017 pertaining to venous blood lead testing performed on the systems produced by Magellan... 
 Printer Friendly Version
6/28/2017Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal 2017 Operating Results on Thursday, July 27, 2017
CINCINNATI, June 28, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its third quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, July 27, 2017. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.  About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets... 
 Printer Friendly Version
6/6/2017Meridian Bioscience Comments on Recent FDA Posting Related to Magellan Diagnostics
CINCINNATI, June 06, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO).  Meridian Bioscience, Inc. is providing the following clarifying comments on the FDA’s recent recall notice posting. On May 17, 2017 Meridian Bioscience, Inc. commented that its subsidiary, Magellan Diagnostics, was working closely with the U.S. Food and Drug Administration (FDA) regarding the use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems (LeadCare, LeadCare II, Ultra and... 
 Printer Friendly Version
5/17/2017Meridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics
CINCINNATI, May 17, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO).  Meridian Bioscience, Inc.’s subsidiary, Magellan Diagnostics, Inc., is currently working with the U.S. Food and Drug Administration (FDA) regarding use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems.  Magellan’s primary product is the LeadCare II, a point-of-care (CLIA-waived) blood lead testing system, on which the vast majority of tests are performed with capillary blood sample... 
 Printer Friendly Version
5/10/2017Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire
CINCINNATI, May 10, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced it will commence a global search for a new Chief Executive Officer in conjunction with the planned retirement of John A. Kraeutler in accordance with the terms of his employment agreement.  Mr. Kraeutler plans to continue to serve in the capacity of CEO until his successor is found.  Going forward he will be available to assist the new CEO during the transition and onboarding phases, and will r... 
 Printer Friendly Version
5/9/2017Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women
Kickoff panel highlights common risks and what obstetricians can do to help protect their patients CINCINNATI, May 09, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian, has embarked on a major new initiative to increase awareness among obstetricians and pregnant women about the risks of lead poisoning.  The effort is being kicked off today with an expert-led discussion of lead poisoning in pregnancy at... 
 Printer Friendly Version
5/4/2017Meridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of Antigens and Antibodies for Diagnostic Applications
CINCINNATI, May 04, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the most comprehensive product offering of tropical disease biologicals intended for the development and manufacture of point-of-care (POC) diagnostic tests.  This product menu from Meridian Life Science, Inc., a wholly-owned subsidiary of Meridian Bioscience, Inc., of over 150 highest quality biologicals consisting of native, recombinant antigens and antibodies is the most comprehensive offeri... 
 Printer Friendly Version
4/27/2017Meridian Bioscience Reports Second Quarter 2017 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance
GENERAL HIGHLIGHTS CINCINNATI, April 27, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fiscal 2017 second quarter and first six months net revenues of $54.1 and $100.9 million, respectively, increases of 6% and 3%, respectively, from the same period of the prior fiscal year; reported second quarter operating income of $14.2 million, a decrease of 6% from the same period of the prior fiscal year; reported six months operating income of $2... 
 Printer Friendly Version
4/24/2017New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) -- As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation. Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed illumigene® Malaria, a molecular-based... 
 Printer Friendly Version
4/17/2017ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) will feature impressive results regarding a revolutionary breakthrough in the world of malaria detection. His presentation at ECCMID is scheduled for April 25, 2017, which is also World Malaria Day. Dr. ... 
 Printer Friendly Version
3/29/2017Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal 2017 Operating Results on Thursday, April 27, 2017
CINCINNATI, March 29, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, April 27, 2017. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.  About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, mark... 
 Printer Friendly Version
3/27/2017Bioline Launches New JetSeq DNA Quantification Kits
CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio for Next Generation Sequencing (NGS) sample preparation. The new JetSeq™ Library Quantification Kit is a qPCR-based assay that provides fast, accurate and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina compatible NGS libraries. The JetSeq™ Libr... 
 Printer Friendly Version
3/7/2017Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa
CINCINNATI, March 07, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian since March 2016, has signed an exclusive distribution agreement with Biofirm Technologies, one of the leading providers of laboratory equipment, consumables, reagents, and medical equipment in East and Central Africa. Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA cleared, rapid and portable system capa... 
 Printer Friendly Version
2/8/2017Bioline Launches New JetSeq™ DNA Library Preparation Kits
CINCINNATI, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the JetSeq™ DNA Library Preparation portfolio for Next Generation Sequencing (NGS) sample preparation. Developed in collaboration with Oxford Gene Technology (OGT), the new JetSeq™ DNA Library Preparation Kits use pre-optimized buffers to provide maximum reaction efficiency and highest conversion rates, enabling the pr... 
 Printer Friendly Version
2/3/2017Meridian Bioscience Announces the Launch of TruQuick™ Rapid Tests for Asia Pacific
CINCINNATI, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of TruQuick™, a comprehensive point-of-care product menu of rapid tests for the diagnosis of tropical, infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac diseases. This product menu will enable Meridian to rapidly expand its product portfolio of high value rapid tests for its commercial operations in Asia Pacific and other emerging markets around th... 
 Printer Friendly Version
1/25/2017Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward
GENERAL HIGHLIGHTS CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year; reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases of 29% compared to the fiscal 20... 
 Printer Friendly Version
1/12/2017Microbix Appoints Meridian Life Science as Distributor in Asia Pacific
Meridian an Exclusive Distributor in China, Hong Kong, Taiwan and Macau TORONTO, ONTARIO--(Marketwired - Jan. 12, 2017) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix"), an innovator of biological products and technologies, today announced it has signed a distribution agreement (the "Agreement") with Meridian Life Science, Inc. ("Meridian") a wholly owned company of Meridian Bioscience, Inc. (NASDAQ:VIVO) a fully integrated global diagnostic and life science company. Under the terms of the Ag... 
 Printer Friendly Version
1/9/2017Bioline Launches the Full Range of EPIK™ miRNA Assays
CINCINNATI, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased to include all of the organisms listed on the miRBase release 21, which represents over 27,00... 
 Printer Friendly Version